Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Raw Materials (2016 - 2018)

Theravance Biopharma (TBPH) has disclosed Raw Materials for 6 consecutive years, with $10.8 million as the latest value for Q3 2018.

  • On a quarterly basis, Raw Materials rose 8.41% to $10.8 million in Q3 2018 year-over-year; TTM through Sep 2018 was $10.8 million, a 8.41% increase, with the full-year FY2017 number at $11.7 million, up 93.32% from a year prior.
  • Raw Materials was $10.8 million for Q3 2018 at Theravance Biopharma, up from $10.6 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $11.7 million in Q4 2017 to a low of $4.0 million in Q1 2014.
  • A 5-year average of $7.6 million and a median of $6.9 million in 2015 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: decreased 21.94% in 2016, then skyrocketed 93.32% in 2017.
  • Theravance Biopharma's Raw Materials stood at $6.8 million in 2014, then rose by 0.57% to $6.9 million in 2015, then dropped by 11.68% to $6.1 million in 2016, then surged by 93.32% to $11.7 million in 2017, then decreased by 8.05% to $10.8 million in 2018.
  • Per Business Quant, the three most recent readings for TBPH's Raw Materials are $10.8 million (Q3 2018), $10.6 million (Q2 2018), and $10.6 million (Q1 2018).